Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G. Salar A, et al. Among authors: avivi i. J Clin Oncol. 2014 Jun 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. Epub 2014 May 12. J Clin Oncol. 2014. PMID: 24821885 Clinical Trial.
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, Smith R, Pfreundschuh M. Lugtenburg P, et al. Among authors: avivi i. Haematologica. 2017 Nov;102(11):1913-1922. doi: 10.3324/haematol.2017.173583. Epub 2017 Sep 21. Haematologica. 2017. PMID: 28935843 Free PMC article. Clinical Trial.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti GJ, Finke J, Schattenberg A, Fanin R, Cornelissen JJ, Vernant JP, Russell N, Beguin Y, Thomson K, Verdonck LF, Kobbe G, Tilly H, Socié G, Sureda A; EBMT Lymphoma Working Party. Avivi I, et al. Br J Haematol. 2009 Dec;147(5):719-28. doi: 10.1111/j.1365-2141.2009.07905.x. Epub 2009 Sep 30. Br J Haematol. 2009. PMID: 19793383 Free article.
(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.
Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R, Israel O. Weiler-Sagie M, et al. Among authors: avivi i. J Nucl Med. 2010 Jan;51(1):25-30. doi: 10.2967/jnumed.109.067892. Epub 2009 Dec 15. J Nucl Med. 2010. PMID: 20009002 Free article.
Rituximab-induced direct inhibition of T-cell activation.
Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I. Stroopinsky D, et al. Among authors: avivi i. Cancer Immunol Immunother. 2012 Aug;61(8):1233-41. doi: 10.1007/s00262-011-1168-2. Epub 2012 Jan 17. Cancer Immunol Immunother. 2012. PMID: 22249775 Free PMC article. Clinical Trial.
Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I, Stroopinsky D, Katz T. Avivi I, et al. Blood Rev. 2013 Sep;27(5):217-23. doi: 10.1016/j.blre.2013.07.002. Epub 2013 Aug 13. Blood Rev. 2013. PMID: 23953071 Review.
239 results